Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 5 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Autolus Limited maintains a portfolio with 11 pending office actions, primarily focused within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 10 distinct examiners, which is a higher number than the 5 distinct art units involved. The 11 pending office actions are spread such that the number of examiners is nearly equal to the number of actions.
The busiest examiner for this portfolio is WESTON, ALYSSA G, who is currently managing 2 busiest examiner pending actions. This count of 2 busiest examiner pending actions is lower than the total 11 pending office actions. While the 11 pending office actions are numerous, the use of 10 distinct examiners means the workload is not concentrated under one person. The 5 distinct art units indicate that the 11 pending office actions span multiple technical classifications. Practitioners should note that the 10 distinct examiners will each apply their own interpretation to the matters within the Biotechnology & Pharmaceuticals area. The 2 busiest examiner pending actions handled by WESTON, ALYSSA G represent the largest single examiner assignment in the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 2 (18%) |
| §102 only | 1 (9%) |
| §112 only | 3 (27%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 2 | 59.8% | +50.9% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| SHIN, DANA H | 1 | 27.0% | +27.0% |
| DHAR, MATASHA | 1 | 43.3% | +45.7% |
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279568 | GENERATION OF T-CELLS BY DIRECT REPROGRAMMING FROM FIBROBLASTS AND MSC | MONTANARI, DAVID A | — |
| 17924345 | METHOD | SHIN, DANA H | — |
| 17915689 | METHOD FOR SELECTING CELLS EXPRESSING A NUCLEIC ACID OF INTEREST | WESTON, ALYSSA G | — |
| 16470965 | TRANSCRIPTION SYSTEM | GONZALES, JOSEPHINE MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17601684 | CELL | RAHMAN, MASUDUR | 32d overdue |
| 18597357 | CHIMERIC ANTIGEN RECEPTOR | DUFFY, BRADLEY | — |
| 18590698 | NUCLEIC ACID CONSTRUCT | KELLY, ROBERT M | — |
| 18279568 | GENERATION OF T-CELLS BY DIRECT REPROGRAMMING FROM FIBROBLASTS AND MSC | MONTANARI, DAVID A | — |
| 18160032 | Retroviral And Lentiviral Vectors | MARVICH, MARIA | — |
| 17924345 | METHOD | SHIN, DANA H | — |
| 17915689 | METHOD FOR SELECTING CELLS EXPRESSING A NUCLEIC ACID OF INTEREST | WESTON, ALYSSA G | — |
| 17915637 | CELL | DHAR, MATASHA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1632 | 2 |
| 1631 | 2 |
| 1635 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18597357 | CHIMERIC ANTIGEN RECEPTOR | DUFFY, BRADLEY | — | DP | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18590698 | NUCLEIC ACID CONSTRUCT | KELLY, ROBERT M | — | §112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18279568 | GENERATION OF T-CELLS BY DIRECT REPROGRAMMING FROM FIBROBLASTS AND MSC | MONTANARI, DAVID A | 1632 | §101§102§103 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 18160032 | Retroviral And Lentiviral Vectors | MARVICH, MARIA | 1631 | §102§112DP | Non-Final OA | — | Pending | Jan 26, 2023 |
| 17924345 | METHOD | SHIN, DANA H | 1635 | §103Other | Final Rejection | — | Pending | Nov 09, 2022 |
| 17915689 | METHOD FOR SELECTING CELLS EXPRESSING A NUCLEIC ACID OF INTEREST | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17915637 | CELL | DHAR, MATASHA | 1632 | §103 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17913649 | TRBC BETA ANTIBODY CONJUGATE | GANGLE, BRIAN J | 1645 | §112 | Final Rejection | — | Pending | Sep 22, 2022 |
| 17601684 | CELL | RAHMAN, MASUDUR | 1633 | §112 | Final Rejection | 32d overdue | Pending | Oct 05, 2021 |
| 17436673 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR | WESTON, ALYSSA G | 1633 | §102 | Final Rejection | — | Pending | Sep 07, 2021 |
| 16470965 | TRANSCRIPTION SYSTEM | GONZALES, JOSEPHINE MARIA | 1631 | §103DP | Non-Final OA | — | Pending | Jun 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial